Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2022-08-20 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a notice dated August 20, 2022, addressed to stock exchanges (NSE and BSE) regarding a corrigendum to the notice of an Extra-Ordinary General Meeting (EGM) scheduled for August 26, 2022. It mentions publication of newspaper advertisements and the corrigendum to the EGM notice. The content is primarily an announcement related to the EGM notice correction and dissemination, not the actual meeting materials or results. The document is about informing stakeholders and the public about the corrigendum to the EGM notice, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain financial statements, voting results, or detailed meeting materials.
2022-08-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a corrigendum to the notice of an Extra-Ordinary General Meeting (EGM) scheduled for August 26, 2022. The document details changes to the explanatory statement for items in the EGM notice, specifically related to share allotment information. It references the original EGM notice dated August 01, 2022, and instructs shareholders to read the corrigendum in conjunction with that notice. The document is not the EGM notice itself, nor is it the voting results or the meeting materials, but rather an update or correction to the notice. Given the nature of the document as a correction to a meeting notice, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is about an EGM notice corrigendum, not the actual AGM information, voting results, or proxy solicitation materials. Therefore, the classification is RNS with high confidence.
2022-08-18 English
General updates
Regulatory Filings Classification · 95% confidence The document is an announcement addressed to stock exchanges (BSE and NSE) regarding a new long-term CDMO agreement with Vital Pharma Nordic. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content is a corporate update about a business agreement, not a financial report, audit, or management change. It is a regulatory announcement about a material event under stock exchange regulations, fitting the category of Regulatory Filings (RNS). The document is short (1199 characters) and does not contain financial statements or detailed reports, so it is not an Annual Report, Interim Report, or similar. Therefore, the best classification is Regulatory Filings (RNS).
2022-08-12 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Medicamen Biotech Limited regarding the outcome of a Board Meeting. It includes approval of un-audited financial results for the quarter ended June 30, 2022, along with a limited review report and an investor release. The document also mentions approval of the draft Annual Report for the financial year 2021-22 and details about the upcoming Annual General Meeting (AGM). The content includes substantive financial data such as income, expenses, profit/loss figures, and tax details for the quarter, indicating it is a financial report rather than a mere announcement. The presence of un-audited quarterly financial results with detailed figures aligns with the definition of an Interim / Quarterly Report (IR). Although the document references the draft Annual Report and AGM details, the primary focus and detailed data pertain to the quarterly financial results. Therefore, the correct classification is Interim / Quarterly Report (IR).
2022-08-10 English
Loss of share certificate
Regulatory Filings Classification · 95% confidence The document is a compliance notice under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the stock exchanges about the issuance of duplicate share certificates due to lost original certificates. It contains details of the shareholder, folio number, share certificate numbers, and distinctive numbers. The document is short (1509 characters) and serves as an official notification to the exchanges rather than a financial report or detailed filing. It does not contain financial data, management discussion, or audit information. This type of announcement fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-05 English
General updates
Regulatory Filings Classification · 95% confidence The document is an announcement addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (LODR) Regulations, 2015. It informs about the receipt of a GMP Compliance Certificate from the Ethiopia Food & Drug Authority. The content is a regulatory update about compliance certification, not a financial report, management change, or other specific filings. The document length is short (869 characters) and is clearly an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.